Celyvir, Pexa-Vec (JX-594), and Seneca Valley Virus (NTX-010) have demonstrated promising clinical resultsJX-594 has genetic alterations such as thymidine kinase gene deletion for tumor-selective replication, GM-CSF insertion for immunological stimulation, and β-galactosidase reporter [15,16,17,18]. This evidence concerns the gene CSF2 and neoplasm.